Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $135.0833.

Several research firms recently issued reports on ABVX. Truist Financial set a $140.00 price target on shares of Abivax in a research report on Monday, November 24th. Oppenheimer set a $131.00 price target on Abivax in a research report on Thursday, January 8th. Barclays assumed coverage on Abivax in a research note on Monday, October 13th. They set an “overweight” rating and a $142.00 price objective for the company. JMP Securities boosted their target price on shares of Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a research note on Thursday, September 25th. Finally, Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th.

Institutional Investors Weigh In On Abivax

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after acquiring an additional 56,235 shares during the period. Woodline Partners LP boosted its holdings in Abivax by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after acquiring an additional 153,788 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Abivax in the second quarter valued at about $139,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Trading Up 1.4%

Shares of ABVX opened at $119.64 on Wednesday. The stock’s 50-day moving average price is $120.97 and its 200 day moving average price is $87.21. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $9.32 billion, a price-to-earnings ratio of -28.62 and a beta of 0.68. Abivax has a 12-month low of $4.77 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. As a group, research analysts predict that Abivax will post -2.83 earnings per share for the current year.

Abivax News Roundup

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Media reports that Eli Lilly is interested in a multi‑billion euro/dollar bid for Abivax have driven sharp buying interest; renewed M&A chatter is the main catalyst lifting the stock. Abivax stock rockets 30% on Eli Lilly takeover speculation
• Positive Sentiment: Major press coverage that cited a possible ~$17.5B bid (and broad M&A interest) amplified buying momentum and volatility in early trading. Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid
• Positive Sentiment: An analyst price‑target increase provides additional support for the rally (higher target can validate upside expectations). Abivax (NASDAQ:ABVX) Price Target Raised to $145.00
• Positive Sentiment: Fundamental bull case reiterated: a Seeking Alpha piece reminds investors that obefazimod’s strong ulcerative colitis data and upcoming catalysts (Phase 3 maintenance topline, potential NDA/MAA filings, Phase 2b Crohn’s results) make Abivax an attractive stand‑alone investment and plausible M&A target. Abivax: Don’t Just Buy The Rumor, Buy The Fundamentals
• Neutral Sentiment: Short interest rose in December to ~2.91M shares (~3.7% of float), implying some bearish positioning that could amplify moves in either direction; short‑interest ratio ~1.7 days. (Data summary)
• Neutral Sentiment: January short‑interest figures reported as zero appear erroneous or incomplete — treat recent short‑interest updates with caution until exchanges confirm accurate filings. (Data summary)
• Negative Sentiment: French finance ministry said it has received no investment‑approval request for Abivax and had no contact with Eli Lilly, directly undercutting the takeover narrative and adding uncertainty about deal probability. France has had no request for investment approval in biotech Abivax – official
• Negative Sentiment: Lifesci Capital trimmed earnings estimates for Abivax, which could temper some expectations around near‑term financial forecasts and valuations. Lifesci Capital Decreases Earnings Estimates for Abivax

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.